NEW ORLEANS--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported data from a clinical trial evaluating a VELCADE based combination for patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL). The VERTICAL1 Phase II trial evaluates a novel three-drug combination of VELCADE, rituximab and bendamustine (VRB), which reported an 86 percent overall response rate (ORR) and 53 percent complete response (CR) rate in patients with relapsed or refractory follicular lymphoma (FL). These data were presented at the 51st Annual Meeting of the American Society of Hematology (ASH), held December 5-8, 2009 in New Orleans, Louisiana.
